This Article Full Text (PDF) All Versions of this Article: 1076029607304408v1 14/1/55    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cuderman, T. V. Articles by Stegnar, M. Search for Related Content PubMed PubMed Citation Articles by Cuderman, T. V. Articles by Stegnar, M. Pubmed/NCBI databases Medline Plus Health Information Deep Vein Thrombosis Social Bookmarking                         What's this?

Hemostasis Activation in Thrombophilic Subjects With or Without a History of Venous Thrombosis

Tjaa Viintin Cuderman, MD

Department of Angiology, University Medical Centre, Ljubljana, Slovenia

Mojca Boi, PhD

Department of Angiology, University Medical Centre, Ljubljana, Slovenia

Polona Peternel, MD, PhD

Department of Angiology, University Medical Centre, Ljubljana, Slovenia

Mojca Stegnar, PhD

Department of Angiology, University Medical Centre, Ljubljana, Slovenia, mojca.stegnar{at}trnovo.kclj.si

Thrombophilia is considered to increase the risk of venous thrombosis (VT) due to hemostasis activation. To determine the level of hemostasis activation in thrombophilic subjects with or without a history of VT, hemostasis activation markers prothrombin fragment 1 and 2 (F1+2), thrombin—antithrombin complex (TAT), and cross-linked fibrin degradation products (D-dimer) were measured in 94 subjects with (patients) and 101 subjects without a history of VT (controls). A total of 34.8% of patients and 14.8% of controls (P = .002) had at least 1 thrombophilic defect (protein C deficiency, activated protein C [APC] resistance, presence of lupus anticoagulants, or prothrombin G20210A polymorphism). The subjects were divided into 4 subgroups: patients with (TF⁺ patients) and without (TF^– patients) thrombophilia, and controls with (TF⁺ controls) and without (TF^– controls) thrombophilia. Hemostasis activation was comparable between all patients and controls (TAT: 2.1 vs 2.6 µg/L; F1+2: 1.0 vs 0.9 nmol/L; D-dimer: 36 vs 37 µg/L, respectively) and between TF⁺ and TF^– patients. However, TF⁺ controls had a significantly higher prevalence of increased hemostasis activation markers compared with TF^– controls (TAT > 4.4 µg/L, 38.4 vs 7.3%; F1+2 > 1.1 nmol/L, 53.8 vs 22.0%; D-dimer > 78 µg/L, 30.7 vs 8.8% of subjects, respectively; all P < .05). After stratification for thrombophilic defects, hemostasis activation was associated with APC resistance in controls and with protein C deficiency in patients. To conclude, thrombophilia was associated with hemostasis activation in controls. We assumed that, in patients, the differences in hemostasis activation between subjects with or without thrombophilia were blurred due to undetermined and unidentified thrombophilic defects.

Key Words: venous thrombosis • thrombophilia • hemostasis activation • markers

This version was published on January 1, 2008

Clinical and Applied Thrombosis/Hemostasis, Vol. 14, No. 1, 55-62 (2008)
DOI: 10.1177/1076029607304408


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Dompmartin, F. Ballieux, P. Thibon, A. Lequerrec, C. Hermans, P. Clapuyt, M.-T. Barrellier, F. Hammer, D. Labbe, M. Vikkula, et al. Elevated D-dimer Level in the Differential Diagnosis of Venous Malformations Arch Dermatol, November 1, 2009; 145(11): 1239 - 1244. [Abstract] [Full Text] [PDF]